Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG021
- Development stage
- Preclinical
- Lead developer
- Rigerna Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RG021 is an investigational RNA-based therapeutic candidate being developed by Suzhou Xuanjing Biotechnology (also known as Rigerna Biotech). It is part of the company's kidney-targeted delivery platform, which is designed to deliver oligonucleotide therapeutics specifically to renal tissues. While the specific biological target and molecular mechanism of action remain undisclosed by the developer, the candidate is intended for the treatment of various kidney-related diseases. As an asset in Rigerna's early-stage pipeline, it leverages the company's expertise in RNA interference (RNAi) or antisense technologies to modulate disease-associated gene expression in the kidney.
Beyond the preview
Go deeper on RG021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RG021.